이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Primary Sclerosing Cholangitis After Liver Transplant With Oral Vancomycin (PROP-LT)

2026년 11월 13일 업데이트: Yael R. Nobel

Preventing Recurrence of Primary Sclerosing Cholangitis After Liver Transplant (PROP-LT): a Phase 1, Open-label, Controlled Study of Oral Vancomycin

Primary Objective:

  • To evaluate safety of a 4-week course of oral vancomycin (250 mg 3 times daily [TID]) in liver transplant recipients who were transplanted for Primary Sclerosing Cholangitis (PSC).

Secondary Objectives:

  • To determine tolerability and adherence to a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC.
  • To assess vancomycin resistant enterococcus (VRE) colonization status over time.
  • To assess the impact of oral vancomycin on stool microbiome composition, diversity, and function.
  • To assess impact of oral vancomycin on microbial metabolite concentrations in blood and stool.
  • To assess impact of oral vancomycin on liver-related biochemical markers.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

Primary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic liver disease characterized by inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts, often associated with inflammatory bowel disease (IBD). A subset of patients ultimately require liver transplantation, yet rPSC occurs in approximately 25-30% of transplant recipients and can lead to graft failure and re-transplantation.

There is increasing evidence that the gut microbiome plays a role in PSC and rPSC pathogenesis. Altered microbiota composition has been identified in patients with PSC. This association is true not only in patients with PSC compared to controls, but also in patients with PSC-IBD compared to patients with IBD-no PSC, indicating a true association with the liver disease itself. Compared to patients with PSC who do not develop post-transplant recurrence, patients who will develop rPSC have altered microbiome composition at the time of liver transplant. Microbial manipulation-including oral antibiotics, fecal microbiota transplantation, and other strategies-has emerged as a potential therapeutic avenue in native liver PSC. In particular, there is mounting interest in oral vancomycin (OV) as a treatment for PSC, as several case reports/case series and a few small trials have demonstrated that OV is associated with reductions in alkaline phosphatase and other markers of liver injury. This effect may be mediated by the impact of OV on bile acid metabolism, short-chain fatty acid production, and/or prevalence of specific bacterial taxa such as Enterococcus gallinarum, a vancomycin-sensitive microbe that has been associated with PSC.

In case reports of patients with post-transplant rPSC, use of OV was also associated with improvement in biochemical markers of liver disease activity. Liver transplant recipients represent a specialized population with unique medication exposures and microbiome composition. While short course of OV are safely used in liver transplant recipients for the treatment of Clostridioides difficile, no prospective study has systematically examined safety, tolerability, microbiome changes, and hepatic effects of OV in liver transplant recipients transplanted for PSC.

연구 유형

중재적

등록 (추정된)

21

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • New York
      • New York, New York, 미국, 10032
        • Columbia University
        • 연락하다:
        • 수석 연구원:
          • Yael Nobel, MD, MS

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age ≥ 18 years

  • Ability to provide written, informed consent.

  • History of orthotopic liver transplantation within 1 to 10 years prior to enrollment (i.e. study drug initiation)

  • Diagnosis of PSC as the underlying liver disease leading to liver transplantation, based on compatible imaging findings (magnetic resonance cholangiopancreatography [MRCP], endoscopic retrograde cholangiopancreatography [ERCP], percutaneous transhepatic cholangiogram [PTC]), liver histology, and/or clinician judgment

  • Subjects with or without IBD may be enrolled. IBD diagnosis with a minimum disease duration of 6 months as assessed by endoscopy/histology. IBD should be in clinical remission or mildly active according to accepted clinical scores and/or clinician judgment.

  • Stable liver graft function, as determined by ALL of the following criteria:

    • No episodes of acute rejection within 6 months prior to enrollment, based on liver histology and/or clinical signs or symptoms
    • No episodes of cholangitis within 6 months prior to study enrollment, based on positive bacterial cultures, compatible imaging, and/or clinical signs or symptoms
    • No intervention for biliary obstruction (e.g. ERCP, PTC, surgical intervention) within 6 months prior to study enrollment.
    • Stable liver biochemistries within 6 months prior to study enrollment, as determined by: ALP <5x ULN
    • Absence of histologic or imaging findings suggestive of cirrhosis

Exclusion Criteria:

  • History of colon resection at any time prior to study enrollment or presence of ileal/colonic diversion within 12 months prior to study enrollment
  • Documented VRE infection within 12 months prior to study enrollment
  • Documented C. difficile infection within 3 months prior to study enrollment
  • Systemic antibiotic exposure within 3 months prior to study enrollment
  • Change in any transplant or IBD-related immunosuppression or its dosing within 30 days prior to study enrollment
  • Currently taking oral vancomycin
  • Allergy or intolerance to vancomycin
  • Treatment with any investigational drug within 3 months prior to study enrollment
  • Severe renal dysfunction (eGFR <30 mL/min/1.73 m²) or on dialysis
  • Any active malignancy
  • Pregnant or breastfeeding Page 8
  • Any condition that, in the investigator's judgment, would make participation unsafe or interfere with adherence (e.g., severe frailty, uncontrolled psychiatric disease, inability to adhere to TID dosing)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Study Arm - Oral Vancomycin

Patients in study arm will be assigned to receive study drug.

Vancomycin 250 mg orally three times per day (TID, 750 mg/day), with doses spaced approximately 8 hours apart (e.g., morning, midday, evening), for a total duration of 4 weeks. Missed doses will not be made up; participants will be instructed to resume the next scheduled dose.

Vancomycin is a glycopeptide antibiotic supplied as oral capsules 250 mg. It acts by inhibiting bacterial cell wall synthesis. Oral vancomycin is minimally absorbed in patients with intact gut mucosa, resulting in high intraluminal concentrations.

다른 이름들:
  • VANCOCIN®
  • vancomycin hydrochloride
간섭 없음: Control Arm - No Drug

Patients in control arm will be assigned to receive no drug.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Proportion of patients experiencing any treatment-related adverse event of grade ≥2
기간: Up to 4 weeks

This is to evaluate safety of a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC. The assessments will be using CTCAE v6.0 grading in the study arm receiving vancomycin compared to the control arm. Percentage (or the number) of study participants who experience related AEs of grade > or = 2 will be tallied and calculated.

Up to 4 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
Change in patient-reported short form-36 symptom questionnaire score
기간: Baseline to 4 weeks, baseline to 8 weeks

To determine tolerability to a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC. The clinical outcomes will be recorded using the SF-36 questionnaire. SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. Items are scored 0-100 with higher scores indicating a more favorable health state.

Baseline to 4 weeks, baseline to 8 weeks
Proportion of participants who complete 4 weeks of oral vancomycin with ≥ 80% of planned doses
기간: Up to 4 weeks

To determine adherence to a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC. The completion of study treatment will be defined, assessed and tallied by self-report and/or pill count.

Up to 4 weeks
Proportion of participants with VRE Colonization Status
기간: Baseline, Week 4, and Week 8

The status will be determined by the presence or absence of vancomycin-resistant Enterococcus (VRE) colonization based on stool sample or rectal swab testing. The result will be positive or negative. The participants with positive results will be tallied.

Baseline, Week 4, and Week 8
Proportion of participants with changes in Stool Microbiome Composition and Diversity
기간: Baseline to 4 weeks, Baseline to 8 weeks

Proportion of participants with change in microbiome composition from baseline to subsequent timepoints as assessed by alpha and beta diversity, differential taxa abundance, and/or changes in genes and gene pathways.

Baseline to 4 weeks, Baseline to 8 weeks
Proportion of participants with change in liver-related biochemical markers
기간: Baseline and 4 weeks, Baseline and 8 weeks

Participants with change in ALP, ALT, and/or GGT (particularly a decrease in ALP) will be tallied and calculated.

Baseline and 4 weeks, Baseline and 8 weeks
Proportion of participants with change in microbial metabolite concentrations.
기간: Baseline and 4 weeks, Baseline and 8 weeks

Participants with changes in microbial metabolite such as short chain fatty acids and bile acids will be tallied and calculated.

Baseline and 4 weeks, Baseline and 8 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Yael R Nobel, M.D., M.S., Assistant Professor of Medicine Center for Liver Disease and Transplantation

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 1일

기본 완료 (추정된)

2027년 11월 1일

연구 완료 (추정된)

2030년 11월 1일

연구 등록 날짜

최초 제출

2026년 11월 13일

QC 기준을 충족하는 최초 제출

2026년 11월 13일

처음 게시됨 (실제)

2026년 11월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 13일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • ACYY2503

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .